Structure via PubChem · Public domain (PubChem)
amdoxovir
Sign in to saveAlso known as DAPD
Amdoxovir is a pharmaceutical drug that has undergone research for the treatment of HIV/AIDS. It acts as a nucleoside reverse transcriptase inhibitor (NRTI). The drug was discovered by Raymond F. Schinazi (Emory University) and C.K. Chu (University of Georgia) and developed by RFS Pharma.
Chemical data
- Formula
- C9H12N6O3
- Molecular weight
- 252.23 g/mol
- IUPAC name
- [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
- SMILES
- C1[C@@H](O[C@@H](O1)CO)N2C=NC3=C(N=C(N=C32)N)N
- InChIKey
- RLAHNGKRJJEIJL-RFZPGFLSSA-N
- XLogP
- -1.2
- Polar surface area
- 134 Ų
- H-bond donors
- 3
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- HIV infection
via ChEMBL · EBI
Wikidata facts
- Mass
- 252.097
Show 4 more facts
- chemical formula
- C₉H₁₂N₆O₃
- isomeric SMILES
- C1[C@@H](O[C@@H](O1)CO)N2C=NC3=C2N=C(N=C3N)N
- canonical SMILES
- C1C(OC(O1)CO)N2C=NC3=C2N=C(N=C3N)N
- Commons category
- Amdoxovir
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Amdoxovir is a pharmaceutical drug that has undergone research for the treatment of HIV/AIDS. It acts as a nucleoside reverse transcriptase inhibitor (NRTI). The drug was discovered by Raymond F. Schinazi (Emory University) and C.K. Chu (University of Georgia) and developed by RFS Pharma.
Amdoxovir was in advanced Phase II clinical trials around 2010. In 2013, a Phase II trial was terminated and another was withdrawn before it started. No further studies appear to have been done.
Excerpted from Wikipedia’s “amdoxovir” article, available under the CC BY-SA 4.0 licence.